Remepy has closed a $36m Series A financing round to accelerate its pharmaceutical co-development partnerships and expand its hybrid drug pipeline. The proceeds will also be used to fund Remepy’s lead product Hybridopa’s global Phase III clinical trial targeting Parkinson’s disease (PD). It is set to commence in the fourth quarter of 2026. The latest funding brings the total capital raised by the company to $62m. The Series A round was led by OG Venture Partners and M Ventures, Merck KGaA, Da

The US Food and Drug Administration (FDA) has granted priority review designation for the new drug application for tinlarebant (LBS-008; Belite Bio) for the treatment of Stargardt Disease Type 1 (STGD1). The FDA has set a Prescription Drug User Fee Act date of February 12, 2027. According to the company, the filing was based on the results from the phase 3 DRAGON trial, which evaluated tinlarebant for the treatment of STGD1. In the study, tinlarebant demonstrated a statistically significant and

China-based IASO Biotechnology has completed the acquisition of MediSix Therapeutics, a Singapore-based immune cell engineering company, adding a proprietary T-cell fratricide-prevention platform and a Phase I clinical asset targeting CD7-positive T-cell malignancies to its existing CAR-T portfolio. The deal extends IASO Bio's cell therapy footprint beyond its approved anti-BCMA product into hematologic indications where conventional CAR-T approaches have been technically constrained. Financial

VEPPANU is the first and only FDA-approved PROTAC and has the potential to become an important new treatment option for adult patients with 2L+ ER+/HER2-, ESR1-mutated mBC Aug. 11, 2026 -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced VEPPANU (vepdegestrant) is now available by prescription in the United States for the treatment of adults with estrogen receptor-positive (ER+)/human epidermal grow

Forge Life Science Partners leads $50 million Series B financing Lead program is an oral, selective IGF-1R inhibitor for thyroid eye disease Khartis Therapeutics, a biotechnology company developing both first- and best-in-class oral small molecule medicines for immunological and chronic diseases, announced today that it has raised $50 million in Series B financing. The round was led by Forge Life Science Partners, with participation from Longwood Fund and Alexandria Venture Investments, alongsi

- All 56 planned participants enrolled approximately five months after first patient dosing - Topline Phase 2 data expected in late 2026 - Positive data could support expansion of CNT201 into Peyronie's disease and cellulite Aug. 17, 2026 -- Connext, a specialty therapeutics company focused on developing innovative therapies for significant unmet medical needs, today announced that it has completed enrollment in the Phase 2 portion of its ongoing Phase 1/2 clinical trial evaluating CNT201 for t

Aug. 17, 2026 -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational drug UGN-103 (mitomycin) for intravesical solution. UGN-103 is a next-generation mitomycin formulation being developed for the treatment of adults with recurrent low-grade intermediate-r

Shortly after inking a deal to expand its rights to CD38-targeting antibody felzartamab across the globe, Biogen has won approval for the drug's use to treat multiple myeloma (MM) in China. China's National Medical Products Administration (NMPA) on Thursday approved felzartamab in combination with lenalidomide and dexamethasone to treat adults with MM who have received at least one prior line of therapy, according to a report from China Daily. Biogen initially gained ex-China global rights to

Redx Pharma is making its second attempt to go public in a reverse merger, announcing Monday that it will combine with Skye Bioscience to create a new company that will trade on NASDAQ as Fibrx Therapeutics. The deal, expected to close in the fourth quarter, comes more than three years after Redx first tried to combine with another drugmaker. In early 2023, it moved to merge with Jounce Therapeutics, but Concentra Biosciences countered with a takeover bid, ultimately winning out over Redx. Red

Tissue analysis showed significantly higher numbers of myelin-positive cells in ExoPTEN-treated animals compared with controls, providing additional preclinical biological support for previously reported functional recovery Aug. 14, 2026 -- NurExone Biologic Inc. ("NurExone" or the "Company") (TSXV: NRX, OTCQB: NRXBF, FSE: J90), a biotechnology company developing exosome-based regenerative therapies, today announced new preclinical tissue-analysis results that provide additional biological supp